PE20020976A1 - Pirido-pirimidinas 6-sustituidas como inhibidores de quinasas - Google Patents

Pirido-pirimidinas 6-sustituidas como inhibidores de quinasas

Info

Publication number
PE20020976A1
PE20020976A1 PE2002000097A PE2002000097A PE20020976A1 PE 20020976 A1 PE20020976 A1 PE 20020976A1 PE 2002000097 A PE2002000097 A PE 2002000097A PE 2002000097 A PE2002000097 A PE 2002000097A PE 20020976 A1 PE20020976 A1 PE 20020976A1
Authority
PE
Peru
Prior art keywords
alkyl
aryl
aralkyl
difluorophenoxy
pyrid
Prior art date
Application number
PE2002000097A
Other languages
English (en)
Spanish (es)
Inventor
Jian Jeffrey Chen
James Patrick Dunn
David Michael Goldstein
Christoph Martin Stahl
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20020976A1 publication Critical patent/PE20020976A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PE2002000097A 2001-02-12 2002-02-08 Pirido-pirimidinas 6-sustituidas como inhibidores de quinasas PE20020976A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26837501P 2001-02-12 2001-02-12
US33465401P 2001-11-30 2001-11-30

Publications (1)

Publication Number Publication Date
PE20020976A1 true PE20020976A1 (es) 2002-10-29

Family

ID=26953040

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000097A PE20020976A1 (es) 2001-02-12 2002-02-08 Pirido-pirimidinas 6-sustituidas como inhibidores de quinasas

Country Status (31)

Country Link
US (3) US6696566B2 (cg-RX-API-DMAC10.html)
EP (1) EP1361880B1 (cg-RX-API-DMAC10.html)
JP (1) JP4064818B2 (cg-RX-API-DMAC10.html)
KR (1) KR100639772B1 (cg-RX-API-DMAC10.html)
CN (1) CN100376571C (cg-RX-API-DMAC10.html)
AR (1) AR035854A1 (cg-RX-API-DMAC10.html)
AT (1) ATE305303T1 (cg-RX-API-DMAC10.html)
AU (1) AU2002256615B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0207172B8 (cg-RX-API-DMAC10.html)
CA (1) CA2434834C (cg-RX-API-DMAC10.html)
CZ (1) CZ20032416A3 (cg-RX-API-DMAC10.html)
DE (1) DE60206363T2 (cg-RX-API-DMAC10.html)
DK (1) DK1361880T3 (cg-RX-API-DMAC10.html)
ES (1) ES2249574T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20030624B1 (cg-RX-API-DMAC10.html)
HU (1) HU229604B1 (cg-RX-API-DMAC10.html)
IL (2) IL156872A0 (cg-RX-API-DMAC10.html)
JO (1) JO2410B1 (cg-RX-API-DMAC10.html)
MA (1) MA26993A1 (cg-RX-API-DMAC10.html)
MX (1) MXPA03007166A (cg-RX-API-DMAC10.html)
MY (1) MY131518A (cg-RX-API-DMAC10.html)
NO (1) NO326133B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ526961A (cg-RX-API-DMAC10.html)
PA (1) PA8539201A1 (cg-RX-API-DMAC10.html)
PE (1) PE20020976A1 (cg-RX-API-DMAC10.html)
PL (1) PL366918A1 (cg-RX-API-DMAC10.html)
RU (1) RU2269527C2 (cg-RX-API-DMAC10.html)
SK (1) SK11322003A3 (cg-RX-API-DMAC10.html)
WO (1) WO2002064594A2 (cg-RX-API-DMAC10.html)
YU (1) YU63703A (cg-RX-API-DMAC10.html)
ZA (1) ZA200305938B (cg-RX-API-DMAC10.html)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053070B2 (en) * 2000-01-25 2006-05-30 Warner-Lambert Company Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
SK11322003A3 (en) 2001-02-12 2004-10-05 Hoffmann La Roche 6-Substituted pyrido-pyrimidines
NZ534069A (en) * 2002-01-22 2007-03-30 Warner Lambert Co 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones to be used to treat neurodegenerative disorders, viruses and cancer
RU2310657C2 (ru) 2002-04-03 2007-11-20 Ф.Хоффманн-Ля Рош Аг Имидазоконденсированные соединения и фармацевтическая композиция, содержащая их
RU2324695C2 (ru) 2002-08-06 2008-05-20 Ф.Хоффманн-Ля Рош Аг 6-АЛКОКСИПИРИДОПИРИМИДИНЫ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ОБЛАДАЮЩАЯ АКТИВНОСТЬЮ ИНГИБИТОРОВ КИНАЗЫ МАР р38
WO2004060346A2 (en) 2002-12-30 2004-07-22 Angiotech International Ag Drug delivery from rapid gelling polymer composition
PT2476667E (pt) * 2003-02-26 2014-09-18 Sugen Inc Compostos de aminoheteroarilo como inibidores da proteína quinase
ES2279361T3 (es) * 2003-04-16 2007-08-16 F. Hoffmann-La Roche Ag Derivados de (6-(fenoxi)-pirido-3,4-dipirimidin-2-il)-amina como inhibidores de p38 kinasa para el tratamiento de estados inflamatorios tal como artritis reumatoide.
WO2005047284A1 (en) * 2003-11-13 2005-05-26 F. Hoffmann-La Roche Ag Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones
EP1831215A1 (en) * 2004-11-23 2007-09-12 Ranbaxy Laboratories Limited Pyrido[2,3-d]pyrimidines as anti-inflamatory agents
US20060142312A1 (en) * 2004-12-23 2006-06-29 Pfizer Inc C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones
WO2006082492A1 (en) * 2005-02-02 2006-08-10 Ranbaxy Laboratories Limited Azabicyclo derivatives as anti-inflammatory agents
JP5198256B2 (ja) * 2005-05-04 2013-05-15 エボテク エージー 縮合複素環式化合物、並びにそれらの組成物及び使用
WO2007009911A1 (en) * 2005-07-21 2007-01-25 F. Hoffmann-La Roche Ag PYRIDO [2 , 3-D] PYRIMIDINE-2 , 4-DIAMINE COMPOUNDS AS PTPlB INHIBITORS
AU2006279992A1 (en) * 2005-08-09 2007-02-22 Irm Llc Compounds and compositions as protein kinase inhibitors
EP1917245A1 (de) 2005-08-21 2008-05-07 Abbott GmbH & Co. KG Heterocyclische verbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren
JO2783B1 (en) * 2005-09-30 2014-03-15 نوفارتيس ايه جي Compounds 2-Amino-7, 8-dihydro-6H-Bayredo (3,4-D) Pyrimidine-5-Ones
MX2008014908A (es) * 2006-05-26 2009-05-13 Toyama Chemical Co Ltd Compuesto heterociclico nuevo o sal del mismo e intermedio del mismo.
WO2008150260A1 (en) * 2007-06-06 2008-12-11 Gpc Biotech, Inc. 8-oxy-2-aminopyrido (2, 3-d) pyrimidin-7-one derivatives as kinase inhibitors and anticancer agents
WO2008078249A1 (en) * 2006-12-21 2008-07-03 Ranbaxy Laboratories Limited Anti-inflammatory agents
US8022085B2 (en) 2007-05-07 2011-09-20 Amgen Inc. Pyrazolo-pyridinone and pyrazolo-pyrazinone compounds as P38 modulators and methods of use thereof
CA2690327A1 (en) 2007-06-15 2008-12-18 Thomas P. Cleary A novel process for the preparation of 3-amino-pentan-1,5-diol
US8367671B2 (en) 2008-03-21 2013-02-05 Amgen Inc. Pyrazolo[3.4-B]pyrazine compounds as p38 modulators and methods of use as anti-inflamatory agents
EP2112150B1 (en) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
CN102177161A (zh) * 2008-10-22 2011-09-07 霍夫曼-拉罗奇有限公司 Jnk的嘧啶基吡啶酮抑制剂
WO2010071846A2 (en) 2008-12-19 2010-06-24 Afraxis, Inc. Compounds for treating neuropsychiatric conditions
CN102648200A (zh) 2009-10-09 2012-08-22 亚弗克希斯公司 用于治疗cns病症的8-乙基-6-(芳基)吡啶并[2,3-d]嘧啶-7(8h)-酮
KR101754664B1 (ko) 2009-12-18 2017-07-06 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 치환된 피리도〔2,3-d〕피리미딘-7(8h)-온스 및 이의 치료 용도
WO2016015597A1 (en) 2014-07-26 2016-02-04 Sunshine Lake Pharma Co., Ltd. Compounds as cdk small-molecule inhibitors and uses thereof
CN115105601A (zh) * 2016-06-08 2022-09-27 投资支持有限公司 用于治疗癌症的药物组合
CN109803968A (zh) 2016-08-15 2019-05-24 辉瑞公司 吡啶并嘧啶酮cdk2/4/6抑制剂
PE20190421A1 (es) 2016-08-17 2019-03-19 Support Venture Gmbh Metodo para prevenir o tratar la perdida de la audicion
WO2018132550A1 (en) * 2017-01-11 2018-07-19 The General Hospital Corporation Voltage gated sodium channel imaging agents
KR20190137854A (ko) * 2017-04-04 2019-12-11 스트리킨 아게 안과 질병의 예방 또는 치료 방법
AU2018325442B2 (en) * 2017-08-31 2023-04-13 Dana-Farber Cancer Institute, Inc. Inhibitors of EGFR and/or HER2 and methods of use
ES2927715T3 (es) 2017-10-05 2022-11-10 Fulcrum Therapeutics Inc Inhibidores de la quinasa p38 reducen la expresión de dux4 y de los genes que le siguen para el tratamiento de la FSHD
WO2020006210A1 (en) * 2018-06-27 2020-01-02 Tufts Medical Center, Inc. Pyridopyrimidine compounds and methods of their use
US20210267983A1 (en) 2018-07-13 2021-09-02 Kinarus Ag Combinations of ppar agonists and p38 kinase inhibitors for preventing or treating fibrotic diseases
TW202112368A (zh) 2019-06-13 2021-04-01 荷蘭商法西歐知識產權股份有限公司 用於治療有關dux4表現之疾病的抑制劑組合
WO2022034031A1 (en) 2020-08-11 2022-02-17 Kinarus Ag Methods of preventing or treating covid-19 and related viral diseases or disorders
CN120247910B (zh) * 2025-04-01 2026-05-05 赣南师范大学 一种杂环类化合物及其制备方法、应用和防治肿瘤的药物组合物

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4215216A (en) 1979-04-18 1980-07-29 American Home Products Corporation 7,8-Dihydro-2,5,8-trisubstituted-7-oxo-pyrido[2,3-d]pyrimidine-6-carboxylic acid derivatives
US5037826A (en) 1986-10-15 1991-08-06 Schering Corporation 1-substituted naphthyridine and pyridopyrazine derivatives
GB8702758D0 (en) * 1987-02-06 1987-03-11 Wellcome Found Treatment of disease
EP0278686A1 (en) 1987-02-07 1988-08-17 The Wellcome Foundation Limited Pyridopyrimidines methods for their preparation and pharmaceutical formulations thereof
HU221425B (en) * 1990-11-06 2002-10-28 Yamanouchi Pharma Co Ltd Condensed pyrazine derivatives, process for their production and pharmaceutical preparations containing these compounds
WO1993017682A1 (en) 1992-03-04 1993-09-16 Abbott Laboratories Angiotensin ii receptor antagonists
TW299333B (cg-RX-API-DMAC10.html) * 1992-12-29 1997-03-01 Takeda Pharm Industry Co Ltd
IL115256A0 (en) * 1994-11-14 1995-12-31 Warner Lambert Co 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
FI971953A7 (fi) * 1994-11-14 1997-05-12 Warner Lambert Co Proteiinityrosiinikinaasin välittämää soluproliferaatiota inhiboivat 6 -aryyli-pyrido(2,3-d)pyrimidiinit ja naftyridiinit
IL117923A (en) * 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
US5620981A (en) 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
US6107300A (en) 1996-03-27 2000-08-22 Dupont Pharmaceuticals Arylamino fused pyrimidines
US6147080A (en) * 1996-12-18 2000-11-14 Vertex Pharmaceuticals Incorporated Inhibitors of p38
ES2301194T3 (es) 1997-02-05 2008-06-16 Warner-Lambert Company Llc Pirido 2,3-d pirimidinas y 4-aminopirimidinas como inhibidores de la proliferacion celular.
US5945422A (en) 1997-02-05 1999-08-31 Warner-Lambert Company N-oxides of amino containing pyrido 2,3-D! pyrimidines
IL131618A0 (en) 1997-04-16 2001-01-28 Abbott Lab 5,7-Disubstituted aminopyrido [2,3-D] pyrimidine compounds and their use as adenosine kinase inhibitors
TW458977B (en) * 1997-04-16 2001-10-11 Abbott Lab 6,7-disubstituted-4-aminopyrido[2,3-D] pyrimidine compounds
CN1252069A (zh) 1997-04-16 2000-05-03 艾博特公司 5,6,7-三取代的-4-氨基吡啶并[2,3-d]嘧啶化合物
DE69939168D1 (de) 1998-05-26 2008-09-04 Warner Lambert Co Bicyclische pyrimidine und bicyclische 3,4-dihydropyrimidine als inhibitoren der zellvermehrung
AU3951899A (en) 1998-06-19 2000-01-05 Pfizer Products Inc. Pyrrolo(2,3-d)pyrimidine compounds
EP1078923B1 (en) 1999-08-02 2006-03-08 F. Hoffmann-La Roche Ag Process for the preparation of benzothiophene derivatives
US7053070B2 (en) * 2000-01-25 2006-05-30 Warner-Lambert Company Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
AP2002002643A0 (en) * 2000-03-06 2002-12-31 Warner Lambert Co 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors
US6518276B2 (en) * 2000-08-31 2003-02-11 Syntex (U.S.A.) Llc 7-oxo-pyridopyrimidines (II)
SK11322003A3 (en) 2001-02-12 2004-10-05 Hoffmann La Roche 6-Substituted pyrido-pyrimidines
NZ534069A (en) * 2002-01-22 2007-03-30 Warner Lambert Co 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones to be used to treat neurodegenerative disorders, viruses and cancer

Also Published As

Publication number Publication date
US7169794B2 (en) 2007-01-30
HRP20030624B1 (en) 2007-03-31
MA26993A1 (fr) 2004-12-20
HRP20030624A2 (en) 2005-06-30
CN1503672A (zh) 2004-06-09
HUP0303458A3 (en) 2012-12-28
DE60206363T2 (de) 2006-07-06
SK11322003A3 (en) 2004-10-05
ATE305303T1 (de) 2005-10-15
JO2410B1 (en) 2007-06-17
IL156872A0 (en) 2004-02-08
PL366918A1 (en) 2005-02-07
US20070135458A1 (en) 2007-06-14
US6696566B2 (en) 2004-02-24
ES2249574T3 (es) 2006-04-01
EP1361880B1 (en) 2005-09-28
DK1361880T3 (da) 2006-01-23
HUP0303458A2 (hu) 2004-01-28
RU2269527C2 (ru) 2006-02-10
CZ20032416A3 (cs) 2004-07-14
JP4064818B2 (ja) 2008-03-19
MY131518A (en) 2007-08-30
KR20040018254A (ko) 2004-03-02
BRPI0207172B1 (pt) 2019-04-09
HU229604B1 (en) 2014-02-28
YU63703A (sh) 2006-05-25
NO326133B1 (no) 2008-10-06
CA2434834C (en) 2010-09-14
US20040116698A1 (en) 2004-06-17
BR0207172A (pt) 2004-03-30
BRPI0207172B8 (pt) 2021-05-25
CA2434834A1 (en) 2002-08-22
IL156872A (en) 2009-07-20
NO20033540D0 (no) 2003-08-11
RU2003125887A (ru) 2005-03-20
US20030171584A1 (en) 2003-09-11
AU2002256615B2 (en) 2007-09-13
MXPA03007166A (es) 2003-11-18
PA8539201A1 (es) 2004-08-31
HK1066170A1 (en) 2005-03-18
KR100639772B1 (ko) 2006-10-30
CN100376571C (zh) 2008-03-26
ZA200305938B (en) 2005-01-26
US7449581B2 (en) 2008-11-11
EP1361880A2 (en) 2003-11-19
WO2002064594A3 (en) 2003-01-09
WO2002064594A2 (en) 2002-08-22
NZ526961A (en) 2005-03-24
JP2004525896A (ja) 2004-08-26
AR035854A1 (es) 2004-07-21
DE60206363D1 (de) 2006-02-09
NO20033540L (no) 2003-08-11

Similar Documents

Publication Publication Date Title
FR21C1010I2 (fr) 2,4,di-(hetero-) arylamino (-oxy)-5 pyrimidines substitutees utilisees comme agents antineoplasiques
BG103785A (en) Pyrrolo[2,3-d]pyrimidines and their application as tyrosine kinase inhibitors
EA200701991A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ИМИДАЗО [1,5-a]ПИРИДИНОВ, СПОСОБ ИХ ПОЛУЧЕНИЯ И СОДЕРЖАЩИЕ ИХ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ
ES2561507T3 (es) Pirrolo[2,3-b]piridinas y pirrolo[2,3-b]pirimidinas sustituidas con heteroarilo como inhibidores de quinasas Janus
WO2002064590A3 (en) Carboline derivatives
BR9810233A (pt) Pirozolpirimidinonas que inibem fosfodiesterase da guanosina 3`, 5`- monosfofato cìclico do tipo 5 (cgmp pde5) para o tratamento da disfunção sexual.
YU73300A (sh) Biciklični pirimidini i biciklični 3,4-dihidropirimidini kao inhibitori ćelijske proliferacije
NZ601687A (en) Azaindoles useful as inhibitors of janus kinases
MXPA05000814A (es) Inhibidores de quinasas.
CA2434834A1 (en) 6-substituted pyrido-pyrimidines
DE60204760D1 (de) Pyrazolo[4,3-d]pyrimidinon-verbindungen als cgmp pde-inhibitoren
EA200200337A1 (ru) ПРОИЗВОДНЫЕ ПИРАЗОЛО[4,3-d]ПИРИМИДИНА
DE60002969D1 (de) Imidazo[5,1-f][1,2,4]triazinderivate
RU2008145660A (ru) Фармацевтические соединения
RU2009123930A (ru) Химические соединения 637: пиридопиримидиндионы в качестве ингибиторов pde4
PE20011287A1 (es) Derivados de imidazopirimidina y derivados de triazolopirimidina
MY118796A (en) 1,2,4-triazolo [4,3-b] pyrido [3,2-d] pyridazine derivatives and pharmaceutical compositions containing them
BR9807305A (pt) Pirido [2,3-d] pirimidinas e 4-aminopirimidinas como inibidores de proliferação celular.
YU108791A (sh) Pirazolopirimidinon antianginalna jedinjenja
PE20010758A1 (es) DERIVADOS DE DIHIDROPIRIMIDO[4,5-d]PIRIMIDONA SUSTITUIDOS POR HETEROALQUILO COMO INHIBIDORES DE QUINASAS p38
RU2005122901A (ru) Производные пиридино [2,3-] пиримидина в качестве селективных ингибиторов kdr и fgfr
EA200200643A1 (ru) ПИРИДО[2,3-d]ПИРИМИДИН-2,7-ДИАМИНОВЫЕ ИНГИБИТОРЫ КИНАЗ
WO2002064591A3 (en) Carboline derivatives
KR880009019A (ko) 트리시클릭벤즈이미다졸, 이들의 제조방법 및 이들을 함유하는 약리학적 조성물
BR0113078A (pt) Uso de um composto, composto, processo para a preparação do mesmo, composição farmacêutica, e, método para produzir um efeito antiangiogênico e/ou redutor da permeabilidade vascular em um animal de sangue quente

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed